JY
MRKR icon

Jeff Yass’s Marker Therapeutics MRKR Stock Holding History

Jeff Yass’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,170
Closed -$121K – 13612
2021
Q3 		$121K Sell
7,170
-640
-8% -$13.1K ﹤0.01% 11941
2021
Q2 		$218K Sell
7,810
-10,020
-56% -$264K ﹤0.01% 11420
2021
Q1 		$399K Buy
+17,830
New +$408K ﹤0.01% 9993
2020
Q2 		– Sell
-1,260
Closed -$24K – 10619
2020
Q1 		$24K Sell
1,260
-2,670
-68% -$68K ﹤0.01% 9894
2019
Q4 		$113K Sell
3,930
-4,110
-51% -$150K ﹤0.01% 9086
2019
Q3 		$411K Buy
8,040
+2,970
+59% +$176K ﹤0.01% 7695
2019
Q2 		$402K Buy
5,070
+3,340
+193% +$198K ﹤0.01% 7726
2019
Q1 		$114K Buy
+1,730
New +$101K ﹤0.01% 8193

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Jeff Yass's MRKR Position: Q2 2026 in Review

Jeff Yass sold out of Marker Therapeutics (MRKR) in Q2 2026, closing a stake of 48,780 shares — an estimated $63.4K sold.

Jeff Yass first reported a position in MRKR in Q4 2018 and held it in 19 quarters. The position peaked at $505K in Q1 2019. 35 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

  • Jeff Yass reported no remaining Marker Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 48,780 Marker Therapeutics shares in Q2 2026, an estimated $63.4K.
  • Jeff Yass first reported a position in Marker Therapeutics in Q4 2018 and held it in 19 quarters.
  • Jeff Yass's Marker Therapeutics position peaked at $505K in Q1 2019.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.